Manning & Napier Group’s Royalty Pharma RPRX Stock Holding History

Manning & Napier Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-137,007	Closed	-$4.94M	–	282
2023 Q1	$4.94M	Sell	137,007 -193	-0.1%	-$7.16K	0.06%	210
2022 Q4	$5.42M	Sell	137,200 -681	-0.5%	-$28.4K	0.07%	208
2022 Q3	$5.54M	Sell	137,881 -4,844	-3%	-$207K	0.07%	206
2022 Q2	$6M	Buy	+142,725	New	+$5.85M	0.07%	201

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Manning & Napier Group's RPRX Position: Q2 2023 in Review

Manning & Napier Group sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 137,007 shares — an estimated $4.94M sold.

Manning & Napier Group first reported a position in RPRX in Q2 2022 and held it in 4 quarters. The position peaked at $6M in Q2 2022. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Manning & Napier Group reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Manning & Napier Group sold 137,007 Royalty Pharma shares in Q2 2023, an estimated $4.94M.
Manning & Napier Group first reported a position in Royalty Pharma in Q2 2022 and held it in 4 quarters.
Manning & Napier Group's Royalty Pharma position peaked at $6M in Q2 2022.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Manning & Napier Group's 13F filing for Q2 2023, filed 26 Jul 2023.